SCNI on Nasdaq
Scinai Immunotherapeutics Ltd.
Biological products company that raised $3 million in 2023 (SEC Form D). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Inhibrx Biosciences, Inc., SAB Biotherapeutics, Inc. or Cidara Therapeutics, or pick any stock.
- TickerSCNI on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersL31
- Incorporated inIsrael3
- Business addressJerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, L3 000003
- Filer categoryNon-accelerated filer3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Funds for a Modern Economy (FENG) program for our wholly owned Polish subsidiary or securing $3 million to fund the development of PC111.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-202.3%Gross margin2
-575.3%Operating margin2
-633.6%Net margin2
99.2%Revenue growth, 20252
-102.5%Return on equity2
-$6.1MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue45¢$4.0M
- Research and development27¢$2.4M
- Selling, general and admin28¢$2.5M
Out of $1.3M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $1.3M | $658.0K | |
| Cost of revenues | -$4.0M | -$1.2M | |
| Gross profit (loss) | -$2.7M | -$580.0K | |
| Research and development expenses, net | -$2.4M | -$5.5M | -$5.2M |
| Marketing, general and administrative expenses | -$2.5M | -$2.5M | -$4.5M |
| Other income | $9.0K | ||
| Total operating expenses | -$4.9M | -$8.1M | -$9.7M |
| Total operating loss | -$7.5M | -$8.6M | -$9.7M |
| Gain on troubled debt restructuring | $250.0K | $14.8M | |
| Financial income (expenses) net, | -$765.0K | -$1.3M | $3.2M |
| Net Income (Loss) | -$8.3M | $4.8M | -$6.5M |
| Net loss (Income) per ordinary share attributable to shareholders, basic (in Dollars per share) | $0.00 | ||
| Net loss (Income) per ordinary share attributable to shareholders, diluted (in Dollars per share) | $0.00 | ||
| Weighted average number of shares used in computing net loss (income) per share attributable to ordinary shareholders, basic (in Shares) | 9.3B shares | 3.2B shares | 1.6B shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.7M | $2.0M | $4.9M | |
| Restricted cash | $150.0K | $131.0K | ||
| Prepaid expenses and other receivables | $170.0K | $213.0K | ||
| Trade receivables | $73.0K | $83.0K | ||
| Total current assets | $2.1M | $2.4M | ||
| Property, plant and equipment, net | $7.8M | $9.2M | ||
| Operating lease right-of-use assets | $1.8M | $1.9M | ||
| Total non-current assets | $9.6M | $11.1M | ||
| Total assets | $11.6M | $13.4M | ||
| Trade payables | $407.0K | $376.0K | ||
| Operating lease liabilities | $329.0K | $424.0K | ||
| Other payables | $849.0K | $1.0M | ||
| Total current liabilities | $1.6M | $1.8M | ||
| Warrants liability | $3.0K | |||
| Loan from others | $294.0K | $260.0K | ||
| Non-current operating lease liabilities | $1.6M | $1.4M | ||
| Total non-current liabilities | $1.9M | $1.7M | ||
| Preferred shares, value | $5.6M | $5.6M | ||
| Additional paid-in capital | $130.1M | $123.6M | ||
| Accumulated deficit | -$125.8M | -$117.5M | ||
| Accumulated other comprehensive loss | -$1.7M | -$1.7M | ||
| Total shareholders equity | $8.1M | $10.0M | -$4.6M | -$1.8M |
| Total liabilities and shareholders equity | $11.6M | $13.4M | ||
| Ordinary shares, authorized (in Shares) | 100.0B shares | 40.0B shares | ||
| Ordinary shares, issued (in Shares) | 13.9B shares | 3.4B shares | ||
| Ordinary shares, outstanding (in Shares) | 13.9B shares | 3.4B shares | ||
| Preferred shares, authorized (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, issued (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, outstanding (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, redemption amount | $34.0M | $34.0M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.7M | $2.0M | $4.9M | |
| Restricted cash | $150.0K | $131.0K | ||
| Prepaid expenses and other receivables | $170.0K | $213.0K | ||
| Trade receivables | $73.0K | $83.0K | ||
| Total current assets | $2.1M | $2.4M | ||
| Property, plant and equipment, net | $7.8M | $9.2M | ||
| Operating lease right-of-use assets | $1.8M | $1.9M | ||
| Total non-current assets | $9.6M | $11.1M | ||
| Total assets | $11.6M | $13.4M | ||
| Trade payables | $407.0K | $376.0K | ||
| Operating lease liabilities | $329.0K | $424.0K | ||
| Other payables | $849.0K | $1.0M | ||
| Total current liabilities | $1.6M | $1.8M | ||
| Warrants liability | $3.0K | |||
| Loan from others | $294.0K | $260.0K | ||
| Non-current operating lease liabilities | $1.6M | $1.4M | ||
| Total non-current liabilities | $1.9M | $1.7M | ||
| Preferred shares, value | $5.6M | $5.6M | ||
| Additional paid-in capital | $130.1M | $123.6M | ||
| Accumulated deficit | -$125.8M | -$117.5M | ||
| Accumulated other comprehensive loss | -$1.7M | -$1.7M | ||
| Total shareholders equity | $8.1M | $10.0M | -$4.6M | -$1.8M |
| Total liabilities and shareholders equity | $11.6M | $13.4M | ||
| Ordinary shares, authorized (in Shares) | 100.0B shares | 40.0B shares | ||
| Ordinary shares, issued (in Shares) | 13.9B shares | 3.4B shares | ||
| Ordinary shares, outstanding (in Shares) | 13.9B shares | 3.4B shares | ||
| Preferred shares, authorized (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, issued (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, outstanding (in Shares) | 1.0K shares | 1.0K shares | ||
| Preferred shares, redemption amount | $34.0M | $34.0M |
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | -$8.3M | $4.8M | -$6.5M |
| Depreciation of property, plant and equipment | $1.4M | $1.6M | $514.0K |
| SEPA commitment fees | $359.0K | ||
| Financial (income) expense related to loan from others | $33.0K | $1.3M | $401.0K |
| Revaluation of warrants | -$3.0K | -$93.0K | -$4.1M |
| Gain on troubled debt restructuring | -$250.0K | -$14.8M | |
| Share-based compensation | $303.0K | $682.0K | $1.1M |
| Decrease (increase) in trade receivables | $10.0K | -$83.0K | |
| Decrease (increase) in other receivables | $43.0K | $224.0K | -$290.0K |
| Changes in operating lease right-of-use assets | $89.0K | $284.0K | $43.0K |
| Increase (decrease) in trade payables | $31.0K | -$156.0K | -$150.0K |
| Changes in operating lease liabilities | $147.0K | -$314.0K | -$58.0K |
| Increase (decrease) in other payables | -$157.0K | $157.0K | -$341.0K |
| Net cash used in operating activities | -$6.0M | -$6.3M | -$9.4M |
| Purchase of property, plant and equipment | -$24.0K | -$12.0K | -$637.0K |
| Net cash used in investing activities | -$24.0K | -$12.0K | -$637.0K |
| Proceed from exercise of warrants, net | $1.4M | $947.0K | |
| Proceeds from issuance of shares, net | $2.0M | $139.0K | |
| Proceeds from issuance of ordinary shares for SEPA holders, net | $5.8M | ||
| Net cash provided by financing activities | $5.8M | $3.4M | $1.1M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $1.0K | -$9.0K | -$272.0K |
| Increase (decrease) in cash, cash equivalents and restricted cash | -$284.0K | -$2.9M | -$9.2M |
| Interest | $143.0K | $833.0K | |
| Recognition of right-of-use assets and lease liabilities upon exercise of lease extension option | $952.0K | ||
| Reclassification of warrants liability to equity | $398.0K | ||
| Shares issued for SEPA financing agreement | $150.0K | ||
| Loan convert into preferred shares | $5.6M | ||
| Exercise of warrants liability into shares | $801.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Scinai Immunotherapeutics Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerAmir Reichman Jan 3, 2023 to now10
- Chief financial officerUri Ben-Or Jan 3, 2023 to Jan 3, 202311
- Chief operating officerElad Mark Jan 3, 2023 to now12
Board members and other officers (11)
- Chief ScientistTamar Ben-Yedidia Jan 3, 2023 to Jan 3, 202313
- Board memberUri Ben-Or Mar 18, 2026 to now14
- Board memberAdi Raviv Jan 3, 2023 to now15
- Board memberAmir Reichman Jan 3, 2023 to now10
- Board memberAvner Rotman Jan 3, 2023 to Jan 23, 202316
- Board memberGeorge Lowell Jan 3, 2023 to Jan 23, 202317
- Board memberJay Green Jan 3, 2023 to now18
- Board memberMark Germain Jan 3, 2023 to now19
- Board memberMorris C. Laster Jan 3, 2023 to Jan 23, 202320
- Board memberYael Margolin Jan 3, 2023 to now21
- Board memberSamuel J. Moed Jan 5, 2023 to now22
Former names
- BiondVax Pharmaceuticals Ltd.Nov 13, 2014 to Aug 28, 20233
Timeline
- Jan 3, 2023New chief executive Amir Reichman becomes CEO10
Filings
242 filings to the SEC since October 2021: 5 annual reports, 1 quarterly reports, 4 major events, 26 insider forms, 20 large holders, 2 private raises, 184 other. The latest 20:
- Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Oct 5, 2026EFFECT EDGAR
- Sep 24, 2026F-1 REGISTRATION STATEMENT EDGAR
- Sep 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 28, 2026EFFECT EDGAR
- Aug 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 EDGAR
- Aug 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 9, 2026SCHEDULE 13G/A EDGAR
- Jul 1, 2026SCHEDULE 13G/A EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 19, 2026EFFECT EDGAR
- May 19, 2026424B3 PROSPECTUS EDGAR
- May 15, 2026CORRESP EDGAR
The 242 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- LCK JNK 1 LLCSCHEDULE 13G/A, 3 filings Feb 24, 2025 to Jul 9, 202623
- Daniel E. StoneSCHEDULE 13G/A, 9 filings Oct 6, 2022 to Jul 1, 202624
- YA II PN, Ltd.SCHEDULE 13G, 1 filing Mar 26, 202525
- SABBY MANAGEMENT, LLCSCHEDULE 13G, 3 filings Jan 4, 2023 to Jan 3, 202526
- ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202427
- Marius NachtSC 13D/A, 2 filings Jan 11, 2022 to Dec 27, 202228
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARUri Ben-Or, Chief financial officer
- 12SEC EDGARElad Mark, Chief operating officer
- 13SEC EDGARTamar Ben-Yedidia, Chief Scientist
- 14SEC EDGARUri Ben-Or, Board member
- 15SEC EDGARAdi Raviv, Board member
- 16SEC EDGARAvner Rotman, Board member
- 17SEC EDGARGeorge Lowell, Board member
- 18SEC EDGARJay Green, Board member
- 19SEC EDGARMark Germain, Board member
- 20SEC EDGARMorris C. Laster, Board member
- 21SEC EDGARYael Margolin, Board member
- 22SEC EDGARSamuel J. Moed, Board member
- 23
- 24
- 25
- 26
- 27
- 28